Linzess Continues On Strong Launch Trajectory, Says Ironwood/Forest
This article was originally published in The Pink Sheet Daily
Executive Summary
Both Ironwood and its specialty pharma partner Forest Laboratories are tying their future to the gastrointestinal drug, which has been gaining traction during its first six months on the market, despite the tough environment for primary care drugs.